| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 1,414.8 | 1,335.6 |
| Gross profit | 870.6 | 817.7 |
| Profit before tax | 539.2 | 446.8 |
| Net income | 418.4 | 348.5 |
| EPS (diluted, $ a share) | $2.92 | $2.37 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +20.0% |
|---|---|
| Revenue, year on year | +5.9% |
| Gross margin | 61.5% |
| Operating margin | 32.0% |
10-Q filed with the SEC, NYSE: RMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Resmed Inc: key numbers
- Share price
- $238.19Close, Nov 16
- Market cap
- $33.5B
- Shares outstanding
- 140.66MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Resmed Inc
All →Resmed Chairman and CEO Michael J. Farrell Sells $1.18M of Stock
Michael J. Farrell, Chairman and CEO, sold 4,993 shares of Resmed Inc at $235.35 a share, worth $1.18M in total on Nov 9, 2026. Shares held after the trade: 479,803 (-1.0%).
- Value
- $1.18M
- Shares
- 4,993
- Price
- $235.35
- Role
- Chairman and CEO
- Holding change
- -1.0%
- Trade date
- Nov 9, 2026
ResMed Earnings Call: Key Takeaways
ResMed delivered strong FY2026 results with 10% revenue growth and introduced FY2027 guidance, balancing core sleep growth against a $75 million headwind from the Astral field safety action.
- Call
- Oct 29, 2026, 4:30 PM ET
Resmed Financial Results
ResMed reported Q1 fiscal year 2027 revenue of $1.4 billion, a 6% increase driven by global demand for sleep and breathing health solutions. The company returned over $1 billion to shareholders through dividends and share repurchases during the quarter, supported by strong free cash flow and the divestiture of MatrixCare.
- Term
- Q1 2027
“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business. Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%.”
Mick Farrell, Resmed’s Chairman and CEO
“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”
Mick Farrell, Resmed’s Chairman and CEO
Resmed Global General Counsel Michael J. Rider Sells $102K of Stock
Michael J. Rider, Global General Counsel, sold 400 shares of Resmed Inc at $255.00 a share, worth $102K in total on Oct 23, 2026. Shares held after the trade: 12,318 (-3.1%).
- Value
- $102K
- Shares
- 400
- Price
- $255.00
- Role
- Global General Counsel
- Holding change
- -3.1%
- Trade date
- Oct 23, 2026
Resmed Chairman and CEO Michael J. Farrell Sells $1.13M of Stock
Michael J. Farrell, Chairman and CEO, sold 4,991 shares of Resmed Inc at $226.33 a share, worth $1.13M in total on Oct 7, 2026. Shares held after the trade: 479,803 (-1.0%).
- Value
- $1.13M
- Shares
- 4,991
- Price
- $226.33
- Role
- Chairman and CEO
- Holding change
- -1.0%
- Trade date
- Oct 7, 2026